Efficacy of Dienogest in Endometriosis: A 12-month Single-center Experience

Primary tabs

SCIENCE
Efficacy of Dienogest in Endometriosis: A 12-month Single-center Experience
Key Take-Away: 

Endometriosis can cause uterine lining cells (endometrium) to grow outside of the uterus causing severe pelvic pain. Dienogest is an oral progestin which exhibits a potent progestogenic effect in the endometrium, and found to be effective and well-tolerated in the treatment of endometriosis.

Dienogest has recently been marketed as a medical treatment for endometriosis.

ABSTRACT: 
Background: 

Dienogest has recently been marketed as a medical treatment for endometriosis.

Given the recent introduction on the market of Dienogest, little data are available regarding its effectiveness in routine clinical practice. The objective of study was to assess the efficacy of dienogest in the management of endometriosis.

Methods: 

This was an observational, single-center, cohort study including a total of 132 women enrolled in the study.  

Women with a surgical diagnosis of endometriosis <24 months or a clinical/instrumental diagnosis of endometriosis and endometriosis-associated pelvic pain score of at least 40 mm on a 100-mm visual analog scale (VAS) at the start of treatment and who had been taking Dienogest 2 mg once daily treatment at the time of study entry for no more than 30 days, consecutively were included in the study. All the participants were observed between September 2013 to September 2014. In accordance with routine practice, women came back for clinical assessment and evaluation of pain after 1 (V1), 3 (V2), and 12 (V3) months.

 

Results: 

A total of 21 of the enrolled patients (n=132) were released from the study during follow-up due to adverse effects. The mean pelvic pain VAS score at baseline was 8.9 (SD 1.3).

The corresponding values were 6.7 (SD 3.2) and 5.7 (SD 3.7) for dyspareunia and dyschezia. The mean VAS scores progressively and significantly decreased to 0.9 (SD 1.6) for pelvic pain, 1.4 (SD 2.1) for dyspareunia and 0.2 (SD 0.9) for dyschezia, respectively, 12 months after the start of treatment.

Conclusion: 

This study confirms that in routine clinical practice, Dienogest 2 mg is an effective and well-tolerated treatment for endometriosis-related pain in women with endometriosis.

 

Source:

Arch Gynecol Obstet. 2017 Jun 29

Link to the source:

https://www.ncbi.nlm.nih.gov/pubmed/28664483

The original title of the article:

Efficacy of dienogest in improving pain in women with endometriosis: a 12-month single-center experience

Authors

Maiorana A et al.

Log in or register to post comments